<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00618956</url>
  </required_header>
  <id_info>
    <org_study_id>MLN-MD-12</org_study_id>
    <nct_id>NCT00618956</nct_id>
  </id_info>
  <brief_title>A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Milnacipran 100 And 200 MG Daily in Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cypress Bioscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Forest Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to accurately assess any changes in blood pressure and pulse at 100 and&#xD;
      200 mg daily dose of milnacipran in patients with fibromyalgia syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is double blind (neither you nor the physician will know if you are receiving&#xD;
      active study drug or placebo, an inactive compound such as a sugar pill) and it is being&#xD;
      conducted at various research centers in the United States.&#xD;
&#xD;
      If the study staff determines that you are eligible and you decide to participate, there will&#xD;
      be approximately 11 study visits in about 3 months. During these visits, you will undergo&#xD;
      routine health exams and complete different kinds of questionnaires.&#xD;
&#xD;
      This study requires that you wear a blood pressure cuff continuously for 24 hours on three&#xD;
      separate occasions. You will also be required to make multiple same-day visits to the study&#xD;
      site on three separate occasions for blood draws.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 4</measure>
    <time_frame>4 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d)</time_frame>
    <description>Change from baseline to Visit 4 in mean systolic blood pressure (SBP) based on ambulatory blood pressure monitor (ABPM) is defined as the mean SBP value at Visit 4 minus the corresponding mean SBP value at baseline in the same 12-hour period post-AM dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 6</measure>
    <time_frame>7 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d, followed by 1 week at 150 mg/d and 2 weeks of 200 mg/d)</time_frame>
    <description>Change from baseline to Visit 6 in mean systolic blood pressure based on ABPM is defined as the mean SBP value at Visit 6 minus the corresponding mean SBP value at baseline in the same 12-hour period post-AM dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Systolic Blood Pressure /Diastolic Blood Pressure for 12-hour Period Post-AM Dose at Visit 4</measure>
    <time_frame>4 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d)</time_frame>
    <description>Change from baseline to Visit 4 in mean SBP/DBP based on ABPM is defined as the mean SBP/DBP values at Visit 4 minus the corresponding mean SBP/DBP values at baseline in the same 12-hour period post-AM dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean SBP/DBP Following 12-hour Period Post-AM Dose at Visit 6</measure>
    <time_frame>7 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d, followed by 1 week at 150 mg/d and 2 weeks of 200 mg/d)</time_frame>
    <description>Change from baseline to Visit 6 in mean SBP/DBP based on ABPM is defined as the mean SBP/DBP value at Visit 6 minus the corresponding mean SBP/DBP value at baseline in the same 12-hour period post-AM dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Heart Rate (HR) Following 24-hour Treatment at Visit 4</measure>
    <time_frame>4 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d)</time_frame>
    <description>Change from baseline to Visit 4 in HR based on ABPM is defined as the mean HR value at Visit 4 minus the corresponding mean HR value at baseline in the same 24-hour period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean HR Following 24-hour Treatment at Visit 6</measure>
    <time_frame>7 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d, followed by 1 week at 150 mg/d and 2 weeks of 200 mg/d)</time_frame>
    <description>Change from baseline to Visit 6 in HR based on ABPM is defined as the mean HR value at Visit 6 minus the corresponding mean HR value at baseline in the same 24-hour period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">321</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milnacipran hydrochloride</intervention_name>
    <description>Milnacipran 100 to 200 mg/day tablet (administered in divided doses, twice daily [BID]), oral administration.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ixel (outside of United States)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  To be eligible to participate in the study, patients must meet the following criteria:&#xD;
&#xD;
               1. Patients may be male or female between the ages of 18 and 70 years, inclusive&#xD;
&#xD;
               2. Patients must have been diagnosed of primary fibromyalgia, as defined by the 1990&#xD;
                  ACR Criteria for the Classification of Fibromyalgia&#xD;
&#xD;
               3. Females must be either postmenopausal (no menses for at least 1 year),&#xD;
                  posthysterectomy, postoophorectomy (bilateral), or, if of childbearing potential,&#xD;
                  must have a negative urine pregnancy test prior to randomization and be using a&#xD;
                  medically acceptable form of contraception (eg, hormonal birth control, IUD,&#xD;
                  double-barrier method [eg, simultaneous use of two of the following: male condom,&#xD;
                  female condom, diaphragm], or a barrier method plus a spermicidal agent&#xD;
                  [contraceptive foam, jelly, or cream])&#xD;
&#xD;
               4. Patients must have the ability to give written informed consent&#xD;
&#xD;
               5. Patients may have hypertension untreated or treated with a maximum of two&#xD;
                  antihypertensive medications. (Note: medications contributing to a combination&#xD;
                  product(s) will each be considered as a separate medication.) If untreated, the&#xD;
                  patient should be stable, with no expectation of initiating treatment during the&#xD;
                  study. If treated, the patient must have been on stable doses of antihypertensive&#xD;
                  medications for at least 2 months, with the expectation that dose adjustments&#xD;
                  will not be necessary for the duration of the study. A patient will be classified&#xD;
                  as hypertensive if the patient is taking antihypertensive medication, has a SBP&#xD;
                  equal to or greater than 130 mm Hg, or has a DBP equal to or greater than 85 mm&#xD;
                  Hg. A patient will be classified as normotensive if he/she is not on&#xD;
                  antihypertensive medication and has a SBP less than 130 mm Hg and DBP less than&#xD;
                  85 mm Hg&#xD;
&#xD;
               6. Patients must have a mean of two sitting SBP measurements of less than 160 mm Hg&#xD;
                  and sitting DBP less than 100 mm Hg at Visit 1 (Screening) and Visit 2&#xD;
                  (Baseline/Randomization) using an automatic office blood pressure monitor&#xD;
&#xD;
               7. Patients must have normal physical examination findings, clinical laboratory&#xD;
                  results, and electrocardiogram (ECG) results from Visit 1 (Screening) or abnormal&#xD;
                  findings judged not clinically significant by the Investigator and documented as&#xD;
                  such in the eCRF&#xD;
&#xD;
               8. Patients must be willing to withdraw from CNS-active therapies marketed as&#xD;
                  antidepressants, including monoamine oxidase inhibitors, tricyclics,&#xD;
                  tetracyclics, selective-serotonin reuptake inhibitors (SSRIs), noradrenaline&#xD;
                  reuptake inhibitors (NARIs), noradrenaline-serotonin reuptake inhibitors (NSRI),&#xD;
                  serotonin-noradrenaline reuptake inhibitors (SNRIs), and St. John's Wort&#xD;
&#xD;
               9. Patients must be willing to withdraw from pregabalin (Lyrica) or gabapentin&#xD;
                  (Neurontin).&#xD;
&#xD;
              10. Patients must be willing to withdraw from stimulant medications such as those&#xD;
                  used to treat attention deficit disorder/attention deficit hyperactivity disorder&#xD;
                  (eg, amphetamine/dextroamphetamine [Adderall], methylphenidate,&#xD;
                  dextroamphetamine) or the fatigue associated with sleep apnea or shift work (eg,&#xD;
                  modafinil)&#xD;
&#xD;
              11. Patients must be willing to withdraw from anorectic agents such as diethylpropion&#xD;
                  , sibutramine (Meridia), and phentermine (Adipex)&#xD;
&#xD;
              12. Patients must be willing to withhold certain medications for the 24 hours before,&#xD;
                  as well as during, any ABPM assessment. These medications include&#xD;
                  phosphodiesterase type 5 inhibitors (eg, Viagra, Levitra, Cialis, Edex, Muse),&#xD;
                  decongestants (eg, pseudoephedrine, phenylephrine), and antimigraine therapies&#xD;
                  (eg, triptans such as Imitrex and Maxalt, ergotamines such as Cafergot and&#xD;
                  Midrin). If, for any reason, the patient takes any of these medications, the ABPM&#xD;
                  visit should be rescheduled so that at least 24 hours have transpired since the&#xD;
                  patient's last use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who meet any of the following criteria will not be eligible to participate in&#xD;
             the study:&#xD;
&#xD;
          -  Psychological/Psychiatric Criteria&#xD;
&#xD;
               1. Patients with a significant risk of suicide, according to the Investigator's&#xD;
                  judgment or based on an answer of 2 or 3 for question 9 of the Beck Depression&#xD;
                  Inventory (BDI) (regarding suicidal ideation) performed at Visit 1 (Screening) or&#xD;
                  Visit 2 (Baseline/Randomization)&#xD;
&#xD;
               2. Patients with a total BDI score greater than 25 at Visit 1 (Screening) or Visit 2&#xD;
                  (Baseline/Randomization)&#xD;
&#xD;
               3. Patients testing positive for illegal substances prior to Visit 2&#xD;
                  (Baseline/Randomization) as demonstrated by positive drug screening or based on&#xD;
                  the Investigator's judgment&#xD;
&#xD;
               4. Patients with any history or behavior that would, in the Investigator's judgment,&#xD;
                  prohibit compliance for the duration of the study&#xD;
&#xD;
          -  Somatic Criteria&#xD;
&#xD;
               1. Patients with myocardial infarction and/or stroke within the past 12 months;&#xD;
                  active cardiac disease (American Heart Association Functional Class 2, 3, or 4);&#xD;
                  congestive heart failure; hemodynamically significant valvular heart disease&#xD;
                  (including patients with a prosthetic heart valve); hypertensive cardiovascular&#xD;
                  disease changes (heart, eyes or kidneys) that in the Investigator's judgment,&#xD;
                  would preclude patient participation; ischemic changes; and/or clinically&#xD;
                  significant cardiac rhythm or conduction abnormalities (including atrial&#xD;
                  fibrillation, left bundle branch block, second- or third-degree heart block)&#xD;
&#xD;
               2. Patients with a mean of two sitting systolic blood pressure (SBP) readings equal&#xD;
                  to or greater than 160 mm Hg or sitting diastolic blood pressure (DBP) equal to&#xD;
                  or greater than 100 mm Hg at Visits 1 (Screening) and 2 (Baseline/Randomization)&#xD;
                  using an automatic office blood pressure monitor&#xD;
&#xD;
               3. Patients with pacemakers&#xD;
&#xD;
               4. Patients with an upper arm circumference less than 24 cm or greater than 42 cm in&#xD;
                  their nondominant arm&#xD;
&#xD;
               5. Patients with evidence of active liver disease (levels of aspartate&#xD;
                  aminotransferase, alanine aminotransferase, and/or alkaline phosphatase &gt; 1.5Ã—&#xD;
                  the upper limit of the normal range for the clinical laboratory performing the&#xD;
                  test)&#xD;
&#xD;
               6. Patients with renal impairment (estimated creatinine clearance &lt; 50 mL/min)&#xD;
&#xD;
               7. Patients with documented autoimmune disease. Patients diagnosed with Hashimoto or&#xD;
                  Grave disease that has been stable for 3 months prior to Visit 1 (Screening) will&#xD;
                  be allowed to enroll&#xD;
&#xD;
               8. Patients with current systemic infection (eg, human immunodeficiency virus,&#xD;
                  hepatitis)&#xD;
&#xD;
               9. Patients with active cancer, except basal cell carcinoma. Patients taking&#xD;
                  prophylactic tamoxifen (or other antiestrogen agents) because of a family history&#xD;
                  of breast cancer or patients taking tamoxifen (or other antiestrogen agents) but&#xD;
                  who are at least 1 year post-active treatment of breast cancer, may be enrolled&#xD;
&#xD;
              10. Patients with a current life expectancy of less than 1 year&#xD;
&#xD;
              11. Patients with active peptic ulcer disease or history of inflammatory bowel&#xD;
                  disease or celiac sprue&#xD;
&#xD;
              12. Patients with pulmonary dysfunction or severe chronic obstructive pulmonary&#xD;
                  disease that, in the Investigator's judgment, could interfere with study&#xD;
                  participation and completion&#xD;
&#xD;
              13. Patients with unstable endocrine disease, including unstable diabetes or thyroid&#xD;
                  disease. Disorders that have been stable for the preceding 3 months will be&#xD;
                  acceptable&#xD;
&#xD;
              14. Male patients with prostatic enlargement or other genitourinary disorders who&#xD;
                  might be at significant risk for dysuria and/or urinary retention while taking&#xD;
                  agents with noradrenaline-reuptake inhibition properties&#xD;
&#xD;
              15. Pregnant or breastfeeding patients&#xD;
&#xD;
              16. Any other conditions (such as epilepsy) that, in the Investigator's judgment,&#xD;
                  would indicate that the patient is unsuitable for the study (eg, might interfere&#xD;
                  with study conduct, confound the interpretation of study results, endanger the&#xD;
                  patient)&#xD;
&#xD;
          -  Treatment-Related Criteria&#xD;
&#xD;
               1. Patients who have received treatment with an experimental agent within the last&#xD;
                  30 days prior to Visit 1 (Screening). Patients who have completed previous&#xD;
                  milnacipran studies (ie, all respective protocol-related study procedures have&#xD;
                  been completed by the patient) are eligible to participate. Any patients who&#xD;
                  failed screening in previous milnacipran studies may be re-evaluated, and&#xD;
                  eligible patients may enroll. Patients currently enrolled in Study MLN-MD-06 are&#xD;
                  not eligible to participate&#xD;
&#xD;
               2. Patients who are receiving concomitant therapy with digitalis (digoxin)&#xD;
                  preparations. (Note: Patients should not undergo washout of digoxin; therefore,&#xD;
                  patients on digoxin should not be enrolled in the study)&#xD;
&#xD;
               3. Patients who are receiving concomitant therapy with monoamine oxidase inhibitors,&#xD;
                  tricyclics, tetracyclics, SSRIs, noradrenaline or noradrenaline-serotonin (NSRI)&#xD;
                  reuptake inhibitors, SNRIs, St. John's Wort, and/or other agents marketed as&#xD;
                  antidepressants and are unable to washout or for whom washout is inadvisable*&#xD;
&#xD;
               4. Patients who are receiving concomitant therapy with pregabalin (Lyrica) or&#xD;
                  gabapentin (Neurontin) and are unable to washout or for whom washout is&#xD;
                  inadvisable*&#xD;
&#xD;
               5. Patients who are receiving concomitant therapy with stimulant medications such as&#xD;
                  those used to treat attention deficit disorder/attention deficit hyperactivity&#xD;
                  disorder (eg, amphetamine/dextroamphetamine [Adderall], methylphenidate,&#xD;
                  dextroamphetamine) or the fatigue associated with sleep apnea or shift work (eg,&#xD;
                  modafinil) and are unable to washout or for whom washout is inadvisable*&#xD;
&#xD;
               6. Patients who are receiving concomitant therapy with anorectic agents such as&#xD;
                  diethylpropion , sibutramine (Meridia), and phentermine (Adipex) and are unable&#xD;
                  to washout or for whom washout is inadvisable*&#xD;
&#xD;
               7. Patients who require the use of agents affecting serotonin pharmacology, such as&#xD;
                  ondansetron (Zofran), granisetron (Kytril), and/or dolasetron (Anzemet)&#xD;
&#xD;
               8. Patients who require doses of guaifenesin greater than 2400 mg/d (approximately&#xD;
                  24 teaspoons)&#xD;
&#xD;
          -  Occupational Criteria&#xD;
&#xD;
             1. Patients whose occupation requires them to work nocturnal hours (eg, 11 PM to 7 AM)&#xD;
&#xD;
          -  ABPM Criteria&#xD;
&#xD;
               1. Patients whose ABPM results at Visit 2 (Baseline/Randomization) do not satisfy&#xD;
                  ABPM inclusion/exclusion criteria outlined in the ABPM training manual&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan Spera</last_name>
    <role>Study Director</role>
    <affiliation>Forest Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site #032</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #035</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #038</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #019</name>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <zip>93449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #016</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #008</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #037</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #025</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #009</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #011</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #036</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #006</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #030</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #018</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #034</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #004</name>
      <address>
        <city>Worchester</city>
        <state>Massachusetts</state>
        <zip>01610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #013</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #021</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #005</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #010</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #029</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #022</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #002</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #017</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>13623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #023</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #007</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #001</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #026</name>
      <address>
        <city>Mechanicsburg</city>
        <state>Pennsylvania</state>
        <zip>17055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #014</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #027</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #024</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #031</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #028</name>
      <address>
        <city>Sugarland</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #003</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #012</name>
      <address>
        <city>Woodstock</city>
        <state>Vermont</state>
        <zip>05091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #020</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #015</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #033</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2008</study_first_posted>
  <results_first_submitted>July 29, 2009</results_first_submitted>
  <results_first_submitted_qc>July 29, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 3, 2009</results_first_posted>
  <last_update_submitted>November 10, 2009</last_update_submitted>
  <last_update_submitted_qc>November 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Allan Spera, Director</name_title>
    <organization>Forest Laboratories, Inc.</organization>
  </responsible_party>
  <keyword>NSRI</keyword>
  <keyword>milnacipran</keyword>
  <keyword>fibromyalgia</keyword>
  <keyword>blood pressure</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milnacipran</mesh_term>
    <mesh_term>Levomilnacipran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period was from October 15, 2007 to April 16, 2008 at 38 centers in the US.</recruitment_details>
      <pre_assignment_details>Following 1-to-4 week washout/single-blind placebo lead-in period, patients were randomized (2:1) to one of the treatment groups, milnacipran or placebo, respectively; and orally treated with study medication for 7-week, double-blind treatment period (Visit 2 to 6), followed by a 2-week single-blind placebo discontinuation period (Visit 6 to 8).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>ITT N= 93, OC analyzed n=89</description>
        </group>
        <group group_id="P2">
          <title>Milnacipran</title>
          <description>Milnacipran 100 to 200 mg/day tablet, oral administration, BID.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not meet criteria, non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>Milnacipran</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="210"/>
            <count group_id="B3" value="321"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.9" spread="11.1"/>
                    <measurement group_id="B2" value="48.3" spread="10.9"/>
                    <measurement group_id="B3" value="48.5" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="307"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 4</title>
        <description>Change from baseline to Visit 4 in mean systolic blood pressure (SBP) based on ambulatory blood pressure monitor (ABPM) is defined as the mean SBP value at Visit 4 minus the corresponding mean SBP value at baseline in the same 12-hour period post-AM dose.</description>
        <time_frame>4 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d)</time_frame>
        <population>The analysis was based on Intent-To-Treat (ITT) population using Observed Cases (OC) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normotensive: ITT N=42, OC analyzed n=39; hypertensive: ITT N=51, OC analyzed n=50</description>
          </group>
          <group group_id="O2">
            <title>Milnacipran</title>
            <description>Normotensive: ITT N=93, OC analyzed n=92; hypertensive: ITT N=88, OC analyzed n=84</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 4</title>
          <description>Change from baseline to Visit 4 in mean systolic blood pressure (SBP) based on ambulatory blood pressure monitor (ABPM) is defined as the mean SBP value at Visit 4 minus the corresponding mean SBP value at baseline in the same 12-hour period post-AM dose.</description>
          <population>The analysis was based on Intent-To-Treat (ITT) population using Observed Cases (OC) approach.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in SBP in Normotensive Patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.0"/>
                    <measurement group_id="O2" value="4.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in SBP in Hypertensive Patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.1"/>
                    <measurement group_id="O2" value="3.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Systolic Blood Pressure /Diastolic Blood Pressure for 12-hour Period Post-AM Dose at Visit 4</title>
        <description>Change from baseline to Visit 4 in mean SBP/DBP based on ABPM is defined as the mean SBP/DBP values at Visit 4 minus the corresponding mean SBP/DBP values at baseline in the same 12-hour period post-AM dose.</description>
        <time_frame>4 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d)</time_frame>
        <population>The analysis was based on Intent-To-Treat (ITT) population using Observed Cases (OC) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>ITT N= 93, OC analyzed n=89</description>
          </group>
          <group group_id="O2">
            <title>Milnacipran</title>
            <description>ITT N= 181, OC analyzed n=176</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Systolic Blood Pressure /Diastolic Blood Pressure for 12-hour Period Post-AM Dose at Visit 4</title>
          <description>Change from baseline to Visit 4 in mean SBP/DBP based on ABPM is defined as the mean SBP/DBP values at Visit 4 minus the corresponding mean SBP/DBP values at baseline in the same 12-hour period post-AM dose.</description>
          <population>The analysis was based on Intent-To-Treat (ITT) population using Observed Cases (OC) approach.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.8"/>
                    <measurement group_id="O2" value="3.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.6"/>
                    <measurement group_id="O2" value="4.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 6</title>
        <description>Change from baseline to Visit 6 in mean systolic blood pressure based on ABPM is defined as the mean SBP value at Visit 6 minus the corresponding mean SBP value at baseline in the same 12-hour period post-AM dose.</description>
        <time_frame>7 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d, followed by 1 week at 150 mg/d and 2 weeks of 200 mg/d)</time_frame>
        <population>The analysis was based on Intent-To-Treat (ITT) population using Observed Cases (OC) approach</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normotensive: ITT N= 42, OC analyzed n=37; hypertensive: ITT N=51, OC analyzed n=47</description>
          </group>
          <group group_id="O2">
            <title>Milnacipran</title>
            <description>Normotensive: ITT N= 93, OC analyzed n=82; hypertensive: ITT N=88, OC analyzed n=80</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 6</title>
          <description>Change from baseline to Visit 6 in mean systolic blood pressure based on ABPM is defined as the mean SBP value at Visit 6 minus the corresponding mean SBP value at baseline in the same 12-hour period post-AM dose.</description>
          <population>The analysis was based on Intent-To-Treat (ITT) population using Observed Cases (OC) approach</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in SBP in Normotensive Patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.3"/>
                    <measurement group_id="O2" value="5.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in SBP in Hypertensive Patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.4"/>
                    <measurement group_id="O2" value="4.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean SBP/DBP Following 12-hour Period Post-AM Dose at Visit 6</title>
        <description>Change from baseline to Visit 6 in mean SBP/DBP based on ABPM is defined as the mean SBP/DBP value at Visit 6 minus the corresponding mean SBP/DBP value at baseline in the same 12-hour period post-AM dose.</description>
        <time_frame>7 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d, followed by 1 week at 150 mg/d and 2 weeks of 200 mg/d)</time_frame>
        <population>The analysis was based on Intent-To-Treat (ITT) population using Observed Cases (OC) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>ITT N=93, OC analyzed n=84</description>
          </group>
          <group group_id="O2">
            <title>Milnacipran</title>
            <description>ITT N=181, OC analyzed n=162</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean SBP/DBP Following 12-hour Period Post-AM Dose at Visit 6</title>
          <description>Change from baseline to Visit 6 in mean SBP/DBP based on ABPM is defined as the mean SBP/DBP value at Visit 6 minus the corresponding mean SBP/DBP value at baseline in the same 12-hour period post-AM dose.</description>
          <population>The analysis was based on Intent-To-Treat (ITT) population using Observed Cases (OC) approach.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.0"/>
                    <measurement group_id="O2" value="5.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.7"/>
                    <measurement group_id="O2" value="5.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Heart Rate (HR) Following 24-hour Treatment at Visit 4</title>
        <description>Change from baseline to Visit 4 in HR based on ABPM is defined as the mean HR value at Visit 4 minus the corresponding mean HR value at baseline in the same 24-hour period.</description>
        <time_frame>4 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d)</time_frame>
        <population>The analysis was based on Intent-To-Treat (ITT) population using Observed Cases (OC) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>ITT N= 93, OC analyzed n=89</description>
          </group>
          <group group_id="O2">
            <title>Milnacipran</title>
            <description>ITT N= 181, OC analyzed n=176</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Heart Rate (HR) Following 24-hour Treatment at Visit 4</title>
          <description>Change from baseline to Visit 4 in HR based on ABPM is defined as the mean HR value at Visit 4 minus the corresponding mean HR value at baseline in the same 24-hour period.</description>
          <population>The analysis was based on Intent-To-Treat (ITT) population using Observed Cases (OC) approach.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Heart Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.6"/>
                    <measurement group_id="O2" value="11.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean HR Following 24-hour Treatment at Visit 6</title>
        <description>Change from baseline to Visit 6 in HR based on ABPM is defined as the mean HR value at Visit 6 minus the corresponding mean HR value at baseline in the same 24-hour period.</description>
        <time_frame>7 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d, followed by 1 week at 150 mg/d and 2 weeks of 200 mg/d)</time_frame>
        <population>The analysis was based on Intent-To-Treat (ITT) population using Observed Cases (OC) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>ITT N=93, OC analyzed n=84</description>
          </group>
          <group group_id="O2">
            <title>Milnacipran</title>
            <description>ITT N=181, OC analyzed n=162</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean HR Following 24-hour Treatment at Visit 6</title>
          <description>Change from baseline to Visit 6 in HR based on ABPM is defined as the mean HR value at Visit 6 minus the corresponding mean HR value at baseline in the same 24-hour period.</description>
          <population>The analysis was based on Intent-To-Treat (ITT) population using Observed Cases (OC) approach.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Heart Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="0.7"/>
                    <measurement group_id="O2" value="12.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 weeks double-blind treatment period followed by 2 weeks single-blind placebo discontinuation period.</time_frame>
      <desc>For SAEs, 3 of 210 affected in double-blind treatment period &amp; 3 of 164 affected in single-blind placebo discontinuation period in milnacipran arm; 1 of 111 affected in double-blind treatment period &amp; 0 of 88 affected in single-blind placebo discontinuation period in placebo arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>ITT N= 93, OC analyzed n=89</description>
        </group>
        <group group_id="E2">
          <title>Milnacipran</title>
          <description>Milnacipran 100 to 200 mg/day tablet, oral administration, BID.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Peritoneal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Periorbital Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Spelnic Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Wrist Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Complicated Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor can review results communications prior to public release &amp; can embargo communications re: results for 90 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential info. Upon sponsor's request, PI shall delete any proprietary info &amp; shall not include raw data in pub. On sponsor's request, PI shall delay submission for any pub while sponsor files patent apps. If trial is multi-center, PI agrees that first publication shall be a multi-center pub.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Palmer, MD</name_or_title>
      <organization>Forest Research Institute, a subsidiary of Forest Laboratories, Inc.</organization>
      <phone>201-427-8218</phone>
      <email>robert.palmer@frx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

